Broad spectrum antivirals The group identified active compounds against emerging viruses (i e Zika, Dengue, SARS COV 2). Analysis of novel foods and circular economy Study the upcycling by products in insects Analysis of the influence insect derived components in the prevention of cardiovascular diseases
We are a synthetic organic group specializing in making molecules with stimuli responsive properties. We assemble molecules to make nanocontainers that are responsive to stimuli such as light, pH and chemical stimuli for applications in drug delivery.
The research group works in the following fields: development of epigenetic and non-epigenetic modulators for the treatment of hematologic tumors. design and synthesis of inhibitors targeting enzymes of the endocannabinoid system for the development of therapeutic agents for neurodegenerative diseases and epilepsy treatment. synthesis of new pharmacological tools for the treatment of rare diseases. Design and synthesis of enzymatic inhibitors or receptor modulators for the development of new infectious agents. Green chemistry methods for the development of new neurodegeneration modulators.
The research group is concerned with the study of the molecular mechanisms of angiogenesis (in neovascular retinopathies and tumors ) and tumor development . Within the group there is also an active line of translational research aimed at the development of bioactive molecules with anti angiogenesis and anti tumor functions.
The research activity mainly concerns with the development of new materials for environmental and biomedical applications, through: chemical and electrochemical deposition of surface layers of organic, inorganic and hybrid materials. the study by voltammetric techniques of inorganic/organometallic complexes and molecules. characterization of composition and structure of solid surfaces and nanoparticles. spectroscopic characterization
The patent application protects nontoxic small molecules (glycomimetics), easily obtained from natural compounds (carbohydrates), which can be used for personalized treatment of glycan-related diseases
The compounds of the present invention are pyrazole[4,3-b]pyridin-6-carboxamide derivatives characterised by direct antibacterial activity against several Gram-positive bacteria
The invention concers compounds that act directly on the extracellular virus.
The invention consists of alternative compounds to nitisinone, for the treatment of both AKU and HT1.
The present invention serves the development of new therapeutic strategies and new non-opioid drugs for the treatment of pain
